We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
- Authors
Burkhard, P; Dominici, P; Borri-Voltattorni, C; Jansonius, J N; Malashkevich, V N
- Abstract
DOPA decarboxylase (DDC) is responsible for the synthesis of the key neurotransmitters dopamine and serotonin via decarboxylation of L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan, respectively. DDC has been implicated in a number of clinic disorders, including Parkinson's disease and hypertension. Peripheral inhibitors of DDC are currently used to treat these diseases. We present the crystal structures of ligand-free DDC and its complex with the anti-Parkinson drug carbiDOPA. The inhibitor is bound to the enzyme by forming a hydrazone linkage with the cofactor, and its catechol ring is deeply buried in the active site cleft. The structures provide the molecular basis for the development of new inhibitors of DDC with better pharmacological characteristics.
- Publication
Nature structural biology, 2001, Vol 8, Issue 11, p963
- ISSN
1072-8368
- Publication type
Journal Article
- DOI
10.1038/nsb1101-963